Overcoming hypoxia-mediated tumor progression: Combinatorial approaches targeting pH regulation, angiogenesis and immune dysfunction

Frontiers in Cell and Developmental Biology

Volumn 4, Issue MAR, 2016, Pages

  McDonald, Paul C ^a   Chafe, Shawn C ^a   Dedhar, Shoukat ^a,b  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Angiogenesis; Carbonic anhydrase IX; Hypoxia; Immune checkpoint inhibitors; Monocarboxylate transporter; Tumor microenvironment

Indexed keywords

EID: 84971594533     PISSN: None     EISSN: 2296634X     Source Type: Journal    
DOI: 10.3389/fcell.2016.00027     Document Type: Review

References (163)

1. Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., Morris, P. G., et al. (2012). A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150, 165-178. doi: 10.1016/j.cell.2012.04.042
2. Ahlskog, J. K. J., Dumelin, C. E., Trüssel, S., Mårlind, J., and Neri, D. (2009). In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. Bioorg. Med. Chem. Lett. 19, 4851-4856. doi: 10.1016/j.bmcl.2009.06.022
3. Baek, G., Tse, Y. F., Hu, Z., Cox, D., Buboltz, N., McCue, P., et al. (2014). MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies. Cell Rep. 9, 2233-2249. doi: 10.1016/j.celrep.2014.11.025
4. Baenke, F., Dubuis, S., Brault, C., Weigelt, B., Dankworth, B., Griffiths, B., et al. (2015). Functional screening identifies MCT4 as a key regulator of breast cancer cell metabolism and survival. J. Pathol. 237, 152-165. doi: 10.1002/path.4562
5. Baginska, J., Viry, E., Berchem, G., Poli, A., Noman, M. Z., van Moer, K., et al. (2013). Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia. Proc. Natl. Acad. Sci. U.S.A. 110, 17450-17455. doi: 10.1073/pnas.1304790110
6. Bailey, K. M., Wojtkowiak, J. W., Hashim, A. I., and Gillies, R. J. (2012). Targeting the metabolic microenvironment of tumors. Adv. Pharmacol. 65, 63-107. doi: 10.1016/B978-0-12-397927-8.00004-X
7. Barsoum, I. B., Hamilton, T. K., Li, X., Cotechini, T., Miles, E. A., Siemens, D. R., et al. (2011). Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. Cancer Res. 71, 7433-7441. doi: 10.1158/0008-5472.CAN-11-2104
8. Barsoum, I. B., Koti, M., Siemens, D. R., and Graham, C. H. (2014a). Mechanisms of hypoxia-mediated immune escape in cancer. Cancer Res. 74, 7185-7190. doi: 10.1158/0008-5472.CAN-14-2598
9. Barsoum, I. B., Smallwood, C. A., Siemens, D. R., and Graham, C. H. (2014b). A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 74, 665-674. doi: 10.1158/0008-5472.CAN-13-0992
10. Birkhäuser, F. D., Koya, R. C., Neufeld, C., Rampersaud, E. N., Lu, X., Micewicz, E. D., et al. (2013). Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM.CAIX in immunocompetent mouse models. J. Immunother. 36, 102-111. doi: 10.1097/CJI.0b013e31827bec97
11. Bola, B. M., Chadwick, A. L., Michopoulos, F., Blount, K. G., Telfer, B. A., Williams, K. J., et al. (2014). Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport. Mol. Cancer Ther. 13, 2805-2816. doi: 10.1158/1535-7163.MCT-13-1091
12. Brahimi-Horn, M. C., Bellot, G., and Pouysségur, J. (2011). Hypoxia and energetic tumour metabolism. Curr. Opin. Genet. Dev. 21, 67-72. doi: 10.1016/j.gde.2010.10.006
13. Brahimi-Horn, M. C., Chiche, J., and Pouyssegur, J. (2007). Hypoxia and cancer. J. Mol. Med. 85, 1301-1307. doi: 10.1007/s00109-007-0281-3
14. Brahmer, J. R., Tykodi, S. S., Chow, L. Q., Hwu, W. J., Topalian, S. L., Hwu, P., et al. (2012). Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465. doi: 10.1056/NEJMoa1200694
15. Bronte, V. (2009). Myeloid-derived suppressor cells in inflammation: uncovering cell subsets with enhanced immunosuppressive functions. Eur. J. Immunol. 39, 2670-2672. doi: 10.1002/eji.200939892
16. Brouwers, A. H., van Eerd, J. E., Frielink, C., Oosterwijk, E., Oyen, W. J., Corstens, F. H., et al. (2004). Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J. Nucl. Med. 45, 327-337
17. Casazza, A., Laoui, D., Wenes, M., Rizzolio, S., Bassani, N., Mambretti, M., et al. (2013). Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 24, 695-709. doi: 10.1016/j.ccr.2013.11.007
18. Chafe, S. C., and Dedhar, S. (2015). Carving out its niche: a role for carbonic anhydrase IX in pre-metastatic niche development. Oncoimmunology 4:e1048955. doi: 10.1080/2162402X.2015.1048955
19. Chafe, S. C., Lou, Y., Sceneay, J., Vallejo, M., Hamilton, M. J., McDonald, P. C., et al. (2015). Carbonic anhydrase IX promotes myeloid-derived suppressor cell mobilization and establishment of a metastatic niche by stimulating G-CSF production. Cancer Res. 75, 996-1008. doi: 10.1158/0008-5472.CAN-14-3000
20. Chang, D. K., Moniz, R. J., Xu, Z., Sun, J., Signoretti, S., Zhu, Q., et al. (2015). Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo. Mol. Cancer 14, 119. doi: 10.1186/s12943-015-0384-3
21. Chiche, J., Ilc, K., Laferrière, J., Trottier, E., Dayan, F., Mazure, N. M., et al. (2009). Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res. 69, 358-368. doi: 10.1158/0008-5472.CAN-08-2470
22. Conley, S. J., Gheordunescu, E., Kakarala, P., Newman, B., Korkaya, H., Heath, A. N., et al. (2012). Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc. Natl. Acad. Sci. U.S.A. 109, 2784-2789. doi: 10.1073/pnas.1018866109
23. Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J. I., Cheng, P., et al. (2010). HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 207, 2439-2453. doi: 10.1084/jem.20100587
24. Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., et al. (2003). Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9, 562-567. doi: 10.1038/nm863
25. Currie, M. J., Beardsley, B. E., Harris, G. C., Gunningham, S. P., Dachs, G. U., Dijkstra, B., et al. (2013). Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity. Hum. Pathol. 44, 402-411. doi: 10.1016/j.humpath.2012.06.004
26. Damaghi, M., Wojtkowiak, J. W., and Gillies, R. J. (2013). pH sensing and regulation in cancer. Front. Physiol. 4:370. doi: 10.3389/fphys.2013.00370
27. Datta, N. R., Ordóñez, S. G., Gaipl, U. S., Paulides, M. M., Crezee, H., Gellermann, J., et al. (2015). Local hyperthermia combined with radiotherapy and-/or chemotherapy: recent advances and promises for the future. Cancer Treat. Rev. 41, 742-753. doi: 10.1016/j.ctrv.2015.05.009
28. Davis, I. D., Wiseman, G. A., Lee, F. T., Gansen, D. N., Hopkins, W., Papenfuss, A. T., et al. (2007). A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immun. 7, 13
29. De Bock, K., Mazzone, M., and Carmeliet, P. (2011). Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat. Rev. Clin. Oncol. 8, 393-404. doi: 10.1038/nrclinonc.2011.83
30. DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., et al. (2011). Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1, 54-67. doi: 10.1158/2159-8274.CD-10-0028
31. De Saedeleer, C. J., Copetti, T., Porporato, P. E., Verrax, J., Feron, O., and Sonveaux, P. (2012). Lactate activates HIF-1 in oxidative but not in Warburg-phenotype human tumor cells. PLoS ONE 7:e46571. doi: 10.1371/journal.pone.0046571
32. Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., and Montero, A. J. (2009). Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58, 49-59. doi: 10.1007/s00262-008-0523-4
33. Doedens, A. L., Stockmann, C., Rubinstein, M. P., Liao, D., Zhang, N., DeNardo, D. G., et al. (2010). Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res. 70, 7465-7475. doi: 10.1158/0008-5472.CAN-10-1439
34. Doherty, J. R., and Cleveland, J. L. (2013). Targeting lactate metabolism for cancer therapeutics. J. Clin. Invest. 123, 3685-3692. doi: 10.1172/JCI69741
35. Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., et al. (2002). Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793-800. doi: 10.1038/nm0902-1039c
36. Doyen, J., Trastour, C., Ettore, F., Peyrottes, I., Toussant, N., Gal, J., et al. (2014). Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome. Biochem. Biophys. Res. Commun. 451, 54-61. doi: 10.1016/j.bbrc.2014.07.050
37. Du, R., Lu, K. V., Petritsch, C., Liu, P., Ganss, R., Passegué, E., et al. (2008). HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13, 206-220. doi: 10.1016/j.ccr.2008.01.034
38. Dubois, L., Peeters, S. G., van Kuijk, S. J., Yaromina, A., Lieuwes, N. G., Saraya, R., et al. (2013). Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: a new concept of dual targeting drugs. Radiother. Oncol. 108, 523-528. doi: 10.1016/j.radonc.2013.06.018
39. Dubois, L., Peeters, S., Lieuwes, N. G., Geusens, N., Thiry, A., Wigfield, S., et al. (2011). Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother. Oncol. 99, 424-431. doi: 10.1016/j.radonc.2011.05.045
40. Ebos, J. M., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., and Kerbel, R. S. (2009). Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239. doi: 10.1016/j.ccr.2009.01.021
41. Erler, J. T., Bennewith, K. L., Cox, T. R., Lang, G., Bird, D., Koong, A., et al. (2009). Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15, 35-44. doi: 10.1016/j.ccr.2008.11.012
42. Estrella, V., Chen, T., Lloyd, M., Wojtkowiak, J., Cornnell, H. H., Ibrahim-Hashim, A., et al. (2013). Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 73, 1524-1535. doi: 10.1158/0008-5472.CAN-12-2796
43. Facciabene, A., Motz, G. T., and Coukos, G. (2012). T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 72, 2162-2171. doi: 10.1158/0008-5472.CAN-11-3687
44. Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L. P., et al. (2011). Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475, 226-230. doi: 10.1038/nature10169
45. Franklin, R. A., Liao, W., Sarkar, A., Kim, M. V., Bivona, M. R., Liu, K., et al. (2014). The cellular and molecular origin of tumor-associated macrophages. Science 344, 921-925. doi: 10.1126/science.1252510
46. Gabrilovich, D. I., and Nagaraj, S. (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162-174. doi: 10.1038/nri2506
47. Gabrilovich, D. I., Ostrand-Rosenberg, S., and Bronte, V. (2012). Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253-268. doi: 10.1038/nri3175
48. Gallagher, F. A., Sladen, H., Kettunen, M. I., Serrao, E. M., Rodrigues, T. B., Wright, A., et al. (2015). carbonic anhydrase activity monitored in vivo by hyperpolarized 13C-magnetic resonance spectroscopy demonstrates its importance for ph regulation in tumors. Cancer Res. 75, 4109-4118. doi: 10.1158/0008-5472.CAN-15-0857
49. Gatenby, R. A., and Gillies, R. J. (2008). A microenvironmental model of carcinogenesis. Nat. Rev. Cancer 8, 56-61. doi: 10.1038/nrc2255
50. Gieling, R. G., Babur, M., Mamnani, L., Burrows, N., Telfer, B. A., Carta, F., et al. (2012). Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J. Med. Chem. 55, 5591-5600. doi: 10.1021/jm300529u
51. Gillies, R. J., and Gatenby, R. A. (2015). Metabolism and its sequelae in cancer evolution and therapy. Cancer J. 21, 88-96. doi: 10.1097/PPO.0000000000000102
52. Gillies, R. J., Robey, I., and Gatenby, R. A. (2008). Causes and consequences of increased glucose metabolism of cancers. J. Nucl. Med. 49(Suppl. 2), 24S-42S. doi: 10.1016/s1359-6349(08)71425-3
53. Gillies, R. J., Verduzco, D., and Gatenby, R. A. (2012). Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat. Rev. Cancer 12, 487-493. doi: 10.1038/nrc3298
54. Grosso, J. F., and Jure-Kunkel, M. N. (2013). CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 13, 5
55. Guo, Z., Wang, H., Meng, F., Li, J., and Zhang, S. (2015). Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. J. Transl. Med. 13, 247. doi: 10.1186/s12967-015-0613-y
56. Halestrap, A. P. (2013). Monocarboxylic acid transport. Compr. Physiol. 3, 1611-1643. doi: 10.1002/cphy.c130008
57. Hanahan, D., and Coussens, L. M. (2012). Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309-322. doi: 10.1016/j.ccr.2012.02.022
58. Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674. doi: 10.1016/j.cell.2011.02.013
59. Harney, A. S., Arwert, E. N., Entenberg, D., Wang, Y., Guo, P., Qian, B. Z., et al. (2015). Real-time imaging reveals local, transient vascular permeability, and tumor cell intravasation stimulated by TIE2hi macrophage-derived VEGFA. Cancer Discov. 5, 932-943. doi: 10.1158/2159-8290.CD-15-0012
60. Hensley, C. T., Faubert, B., Yuan, Q., Lev-Cohain, N., Jin, E., Kim, J., et al. (2016). Metabolic heterogeneity in human lung tumors. Cell 164, 681-694. doi: 10.1016/j.cell.2015.12.034
61. Highfill, S. L., Cui, Y., Giles, A. J., Smith, J. P., Zhang, H., Morse, E., et al. (2014). Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci. Transl. Med. 6:237ra267. doi: 10.1126/scitranslmed.3007974
62. Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723. doi: 10.1056/NEJMoa1003466
63. Hu, Y. L., DeLay, M., Jahangiri, A., Molinaro, A. M., Rose, S. D., Carbonell, W. S., et al. (2012). Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res. 72, 1773-1783. doi: 10.1158/0008-5472.CAN-11-3831
64. Hu-Lieskovan, S., Mok, S., Homet Moreno, B., Tsoi, J., Robert, L., Goedert, L., et al. (2015). Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci. Transl. Med. 7:279ra241. doi: 10.1126/scitranslmed.aaa4691
65. Jain, R. K. (2014). Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26, 605-622. doi: 10.1016/j.ccell.2014.10.006
66. Joyce, J. A., and Fearon, D. T. (2015). T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74-80. doi: 10.1126/science.aaa6204
67. Junttila, M. R., and de Sauvage, F. J. (2013). Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501, 346-354. doi: 10.1038/nature12626
68. Kareva, I., and Hahnfeldt, P. (2013). The emerging 'hallmarks' of metabolic reprogramming and immune evasion: distinct or linked? Cancer Res. 73, 2737-2742. doi: 10.1158/0008-5472.can-12-3696
69. Karim, K., Giribabu, N., Muniandy, S., and Salleh, N. (2016). Estrogen and progesterone differentially regulate carbonic anhydrase II, III, IX, XII, and XIII in ovariectomized rat uteri. Syst. Biol. Reprod. Med. 62, 57-68. doi: 10.3109/19396368.2015.1112699
70. Kerbel, R. S. (2008). Tumor angiogenesis. N. Engl. J. Med. 358, 2039-2049. doi: 10.1056/NEJMra0706596
71. Kim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., et al. (2014). Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl. Acad. Sci. U.S.A. 111, 11774-11779. doi: 10.1073/pnas.1410626111
72. Kim, Y. J., Lee, H. J., Kim, T. M., Eisinger-Mathason, T. S., Zhang, A. Y., Schmidt, B., et al. (2013). Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1alpha. Int. J. Cancer 132, 29-41. doi: 10.1002/ijc.27666
73. Krall, N., Pretto, F., Decurtins, W., Bernardes, G. J., Supuran, C. T., and Neri, D. (2014). A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew. Chem. Int. Ed Engl. 53, 4231-4235. doi: 10.1002/anie.201310709
74. Kroemer, G., and Pouyssegur, J. (2008). Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13, 472-482. doi: 10.1016/j.ccr.2008.05.005
75. Lambert, J. M., and Chari, R. V. (2014). Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J. Med. Chem. 57, 6949-6964. doi: 10.1021/jm500766w
76. Laoui, D., Van Overmeire, E., Di Conza, G., Aldeni, C., Keirsse, J., Morias, Y., et al. (2014). Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. Cancer Res. 74, 24-30. doi: 10.1158/0008-5472.CAN-13-1196
77. Ledaki, I., McIntyre, A., Wigfield, S., Buffa, F., McGowan, S., Baban, D., et al. (2015). Carbonic anhydrase IX induction defines a heterogeneous cancer cell response to hypoxia and mediates stem cell-like properties and sensitivity to HDAC inhibition. Oncotarget 6, 19413-19427. doi: 10.18632/oncotarget.4989
78. Le Floch, R., Chiche, J., Marchiq, I., Naiken, T., Ilc, K., Murray, C. M., et al. (2011). CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc. Natl. Acad. Sci. U.S.A. 108, 16663-16668. doi: 10.1073/pnas.1106123108
79. Lendahl, U., Lee, K. L., Yang, H., and Poellinger, L. (2009). Generating specificity and diversity in the transcriptional response to hypoxia. Nat. Rev. Genet. 10, 821-832. doi: 10.1038/nrg2665
80. Lock, F. E., McDonald, P. C., Lou, Y., Serrano, I., Chafe, S. C., Ostlund, C., et al. (2013). Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene 32, 5210-5219. doi: 10.1038/onc.2012.550
81. Lou, Y., McDonald, P. C., Oloumi, A., Chia, S., Ostlund, C., Ahmadi, A., et al. (2011). Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 71, 3364-3376. doi: 10.1158/0008-5472.CAN-10-4261
82. Lu, H., Forbes, R. A., and Verma, A. (2002). Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J. Biol. Chem. 277, 23111-23115. doi: 10.1074/jbc.M202487200
83. Lu, H., Samanta, D., Xiang, L., Zhang, H., Hu, H., Chen, I., et al. (2015). Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype. Proc. Natl. Acad. Sci. U.S.A. 112, E4600-E4609. doi: 10.1073/pnas.1513433112
84. Mahoney, K. M., Rennert, P. D., and Freeman, G. J. (2015). Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov. 14, 561-584. doi: 10.1038/nrd4591
85. Marchiq, I., and Pouysségur, J. (2015). Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H symporters. J. Mol. Med. (Berl). 94, 155-171. doi: 10.1007/s00109-015-1307-x
86. McDonald, P. C., and Dedhar, S. (2014). Carbonic Anhydrase IX (CAIX) as a mediator of hypoxia-induced stress response in cancer cells. Subcell. Biochem. 75, 255-269. doi: 10.1007/978-94-007-7359-2_13
87. McDonald, P. C., Winum, J. Y., Supuran, C. T., and Dedhar, S. (2012). Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget 3, 84-97. doi: 10.18632/oncotarget.422
88. McIntyre, A., and Harris, A. L. (2015). Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality. EMBO Mol. Med. 7, 368-379. doi: 10.15252/emmm.201404271
89. McIntyre, A., Patiar, S., Wigfield, S., Li, J. L., Ledaki, I., Turley, H., et al. (2012). Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clin. Cancer Res. 18, 3100-3111. doi: 10.1158/1078-0432.CCR-11-1877
90. Messmer, M. N., Netherby, C. S., Banik, D., and Abrams, S. I. (2015). Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy. Cancer Immunol. Immunother. 64, 1-13. doi: 10.1007/s00262-014-1639-3
91. Miles, D., Harbeck, N., Escudier, B., Hurwitz, H., Saltz, L., Van Cutsem, E., et al. (2011). Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J. Clin. Oncol. 29, 83-88. doi: 10.1200/JCO.2010.30.2794
92. Molina, A. M., Lin, X., Korytowsky, B., Matczak, E., Lechuga, M. J., Wiltshire, R., et al. (2014). Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials. Eur. J. Cancer 50, 351-358. doi: 10.1016/j.ejca.2013.08.021
93. Moon, E. J., Sonveaux, P., Porporato, P. E., Danhier, P., Gallez, B., Batinic-Haberle, I., et al. (2010). NADPH oxidase-mediated reactive oxygen species production activates hypoxia-inducible factor-1 (HIF-1) via the ERK pathway after hyperthermia treatment. Proc. Natl. Acad. Sci. U.S.A. 107, 20477-20482. doi: 10.1073/pnas.1006646107
94. Motz, G. T., and Coukos, G. (2013). Deciphering and reversing tumor immune suppression. Immunity 39, 61-73. doi: 10.1016/j.immuni.2013.07.005
95. Movahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stangé, G., Van den Bossche, J., et al. (2010). Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 70, 5728-5739. doi: 10.1158/0008-5472.CAN-09-4672
96. Murdoch, C., Giannoudis, A., and Lewis, C. E. (2004). Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104, 2224-2234. doi: 10.1182/blood-2004-03-1109
97. Muselaers, C. H. J., Boers-Sonderen, M. J., van Oostenbrugge, T. J., Boerman, O. C., Desar, I. M. E., Stillebroer, A. B., et al. (2015). Phase 2 study of lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur. Urol. doi: 10.1016/j.eururo.2015.11.033. [Epub ahead of print]
98. Neri, D., and Supuran, C. T. (2011). Interfering with pH regulation in tumours as a therapeutic strategy. Nat. Rev. Drug Discov. 10, 767-777. doi: 10.1038/nrd3554
99. Ngiow, S. F., Young, A., Jacquelot, N., Yamazaki, T., Enot, D., Zitvogel, L., et al. (2015). A threshold level of intratumor CD8+ T-cell PD1 expression dictates therapeutic response to anti-PD1. Cancer Res. 75, 3800-3811. doi: 10.1158/0008-5472.CAN-15-1082
100. Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., et al. (2014). PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 211, 781-790. doi: 10.1084/jem.20131916
101. Noy, R., and Pollard, J. W. (2014). Tumor-associated macrophages: from mechanisms to therapy. Immunity 41, 49-61. doi: 10.1016/j.immuni.2014.06.010
102. Oosterwijk, E. (2008). Carbonic anhydrase IX/G250/MN: a molecule too good to be true? BJU Int. 101, 527-528. doi: 10.1111/j.1464-410x.2007.07431.x
103. Oosterwijk-Wakka, J. C., Boerman, O. C., Mulders, P. F., and Oosterwijk, E. (2013). Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int. J. Mol. Sci. 14, 11402-11423. doi: 10.3390/ijms140611402
104. Pacchiano, F., Carta, F., McDonald, P. C., Lou, Y., Vullo, D., Scozzafava, A., et al. (2011). Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J. Med. Chem. 54, 1896-1902. doi: 10.1021/jm101541x
105. Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., et al. (2009). Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231. doi: 10.1016/j.ccr.2009.01.027
106. Paez-Ribes, M., Man, S., Xu, P., and Kerbel, R. S. (2015). Potential proinvasive or metastatic effects of preclinical antiangiogenic therapy are prevented by concurrent chemotherapy. Clin. Cancer Res. 21, 5488-5498. doi: 10.1158/1078-0432.CCR-15-0915
107. Palazon, A., Goldrath, A. W., Nizet, V., and Johnson, R. S. (2014). HIF transcription factors, inflammation, and immunity. Immunity 41, 518-528. doi: 10.1016/j.immuni.2014.09.008
108. Palucka, K., and Banchereau, J. (2013). Dendritic-cell-based therapeutic cancer vaccines. Immunity 39, 38-48. doi: 10.1016/j.immuni.2013.07.004
109. Papi, A., Storci, G., Guarnieri, T., De Carolis, S., Bertoni, S., Avenia, N., et al. (2013). Peroxisome proliferator activated receptor-alpha/hypoxia inducible Factor-1alpha interplay sustains carbonic anhydrase IX and apoliprotein e expression in breast cancer stem cells. PLoS ONE 8:e54968. doi: 10.1371/journal.pone.0054968
110. Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264. doi: 10.1038/nrc3239
111. Parks, S. K., Chiche, J., and Pouyssegur, J. (2013). Disrupting proton dynamics and energy metabolism for cancer therapy. Nat. Rev. Cancer 13, 611-623. doi: 10.1038/nrc3579
112. Parks, S. K., Cormerais, Y., Marchiq, I., and Pouysségur, J. (2015). Hypoxia optimises tumour growth by controlling nutrient import and acidic metabolite export. Mol. Aspects Med. 47-48, 3-14. doi: 10.1016/j.mam.2015.12.001
113. Pastorek, J., and Pastorekova, S. (2015). Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use. Semin. Cancer Biol. 31, 52-64. doi: 10.1016/j.semcancer.2014.08.002
114. Pavlova, N. N., and Thompson, C. B. (2016). The emerging hallmarks of cancer metabolism. Cell Metab. 23, 27-47. doi: 10.1016/j.cmet.2015.12.006
115. Payen, V. L., Brisson, L., Dewhirst, M. W., and Sonveaux, P. (2015a). Common responses of tumors and wounds to hypoxia. Cancer J. 21, 75-87. doi: 10.1097/PPO.0000000000000098
116. Payen, V. L., Porporato, P. E., Baselet, B., and Sonveaux, P. (2015b). Metabolic changes associated with tumor metastasis, part 1: tumor pH, glycolysis and the pentose phosphate pathway. Cell. Mol. Life Sci. 73, 1333-1348. doi: 10.1007/s00018-015-2098-5
117. Petrul, H. M., Schatz, C. A., Kopitz, C. C., Adnane, L., McCabe, T. J., Trail, P., et al. (2011). Therapeutic mechanism and efficacy of the antibody drug-conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Mol. Cancer Ther. 11, 340-349. doi: 10.1158/1535-7163.mct-11-0523
118. Polanski, R., Hodgkinson, C. L., Fusi, A., Nonaka, D., Priest, L., Kelly, P., et al. (2014). Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin. Cancer Res. 20, 926-937. doi: 10.1158/1078-0432.CCR-13-2270
119. Pore, N., Jalla, S., Liu, Z., Higgs, B., Sorio, C., Scarpa, A., et al. (2015). In vivo loss of function screening reveals carbonic anhydrase IX as a key modulator of tumor initiating potential in primary pancreatic tumors. Neoplasia 17, 473-480. doi: 10.1016/j.neo.2015.05.001
120. Pouysségur, J., Dayan, F., and Mazure, N. M. (2006). Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441, 437-443. doi: 10.1038/nature04871
121. Proescholdt, M. A., Merrill, M. J., Stoerr, E. M., Lohmeier, A., Pohl, F., and Brawanski, A. (2012). Function of carbonic anhydrase IX in glioblastoma multiforme. Neurooncology 14, 1357-1366. doi: 10.1093/neuonc/nos216
122. Quail, D. F., and Joyce, J. A. (2013). Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423-1437. doi: 10.1038/nm.3394
123. Rami, M., Dubois, L., Parvathaneni, N. K., Alterio, V., van Kuijk, S. J., Monti, S. M., et al. (2013). Hypoxia-targeting carbonic anhydrase IX inhibitors by a new series of nitroimidazole-sulfonamides/sulfamides/sulfamates. J. Med. Chem. 56, 8512-8520. doi: 10.1021/jm4009532
124. Rapisarda, A., Hollingshead, M., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., et al. (2009). Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol. Cancer Ther. 8, 1867-1877. doi: 10.1158/1535-7163.MCT-09-0274
125. Rapisarda, A., and Melillo, G. (2012). Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat. Rev. Clin. Oncol. 9, 378-390. doi: 10.1038/nrclinonc.2012.64
126. Rohan, T. E., Xue, X., Lin, H. M., D'Alfonso, T. M., Ginter, P. S., Oktay, M. H., et al. (2014). Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer. J. Nat. Cancer Inst. 106:dju136. doi: 10.1093/jnci/dju136
127. Samanta, D., Gilkes, D. M., Chaturvedi, P., Xiang, L., and Semenza, G. L. (2014). Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc. Natl. Acad. Sci. U.S.A. 111, E5429-E5438. doi: 10.1073/pnas.1421438111
128. Sceneay, J., Chow, M. T., Chen, A., Halse, H. M., Wong, C. S., Andrews, D. M., et al. (2012). Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res. 72, 3906-3911. doi: 10.1158/0008-5472.CAN-11-3873
129. Schlecker, E., Stojanovic, A., Eisen, C., Quack, C., Falk, C. S., Umansky, V., et al. (2012). Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J. Immunol. 189, 5602-5611. doi: 10.4049/jimmunol.1201018
130. Scott, A. M., Wolchok, J. D., and Old, L. J. (2012). Antibody therapy of cancer. Nat. Rev. Cancer 12, 278-287. doi: 10.1038/nrc3236
131. Sedlakova, O., Svastova, E., Takacova, M., Kopacek, J., Pastorek, J., and Pastorekova, S. (2014). Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors. Front. Physiol. 4:400. doi: 10.3389/fphys.2013.00400
132. Selby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., et al. (2013). Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 1, 32-42. doi: 10.1158/2326-6066.CIR-13-0013
133. Semenza, G. L. (2014). Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu. Rev. Pathol. 9, 47-71. doi: 10.1146/annurev-pathol-012513-104720
134. Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., et al. (2007). Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 25, 911-920. doi: 10.1038/nbt1323
135. Shojaei, F., Wu, X., Qu, X., Kowanetz, M., Yu, L., Tan, M., et al. (2009). G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl. Acad. Sci. U.S.A. 106, 6742-6747. doi: 10.1073/pnas.0902280106
136. Siebels, M., Rohrmann, K., Oberneder, R., Stahler, M., Haseke, N., Beck, J., et al. (2011). A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX(R)) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J. Urol. 29, 121-126. doi: 10.1007/s00345-010-0570-2
137. Siemens, D. R., Hu, N., Sheikhi, A. K., Chung, E., Frederiksen, L. J., Pross, H., et al. (2008). Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: role of nitric oxide. Cancer Res. 68, 4746-4753. doi: 10.1158/0008-5472.CAN-08-0054
138. Sonveaux, P., Végran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., et al. (2008). Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 118, 3930-3942. doi: 10.1172/jci36843
139. Stockmann, C., Doedens, A., Weidemann, A., Zhang, N., Takeda, N., Greenberg, J. I., et al. (2008). Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456, 814-818. doi: 10.1038/nature07445
140. Supuran, C. T. (2012). Inhibition of carbonic anhydrase IX as a novel anticancer mechanism. World J. Clin. Oncol. 3, 98-103. doi: 10.5306/wjco.v3.i7.98
141. Surfus, J. E., Hank, J. A., Oosterwijk, E., Welt, S., Lindstrom, M. J., Albertini, M. R., et al. (1996). Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J. Immunother. Emphasis Tumor Immunol. 19, 184-191. doi: 10.1097/00002371-199605000-00003
142. Svastova, E., and Pastorekova, S. (2013). Carbonic anhydrase IX: a hypoxia-controlled 'catalyst' of cell migration. Cell Adh. Migr. 7, 226-231. doi: 10.4161/cam.23257
143. Swietach, P., Hulikova, A., Vaughan-Jones, R. D., and Harris, A. L. (2010). New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene 29, 6509-6521. doi: 10.1038/onc.2010.455
144. Talmadge, J. E., and Gabrilovich, D. I. (2013). History of myeloid-derived suppressor cells. Nat. Rev. Cancer 13, 739-752. doi: 10.1038/nrc3581
145. Topalian, S. L., Drake, C. G., and Pardoll, D. M. (2015). Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450-461. doi: 10.1016/j.ccell.2015.03.001
146. Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454. doi: 10.1056/NEJMoa1200690
147. Touisni, N., Maresca, A., McDonald, P. C., Lou, Y., Scozzafava, A., Dedhar, S., et al. (2011). Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors. J. Med. Chem. 54, 8271-8277. doi: 10.1021/jm200983e
148. Vaeteewoottacharn, K., Kariya, R., Dana, P., Fujikawa, S., Matsuda, K., Ohkuma, K., et al. (2016). Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma. Tumour Biol. doi: 10.1007/s13277-016-4785-8. [Epub ahead of print]
149. van Beijnum, J. R., Nowak-Sliwinska, P., Huijbers, E. J., Thijssen, V. L., and Griffioen, A. W. (2015). The great escape; the hallmarks of resistance to antiangiogenic therapy. Pharmacol. Rev. 67, 441-461. doi: 10.1124/pr.114.010215
150. Ward, C., Meehan, J., Mullen, P., Supuran, C., Dixon, J. M., Thomas, J. S., et al. (2015). Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models. Oncotarget 6, 24856-24870. doi: 10.18632/oncotarget.4498
151. Webb, B. A., Chimenti, M., Jacobson, M. P., and Barber, D. L. (2011). Dysregulated pH: a perfect storm for cancer progression. Nat. Rev. Cancer 11, 671-677. doi: 10.1038/nrc3110
152. Welti, J., Loges, S., Dimmeler, S., and Carmeliet, P. (2013). Recent molecular discoveries in angiogenesis and anti-angiogenic therapies in cancer. J. Clin. Invest. 123, 3190-3200. doi: 10.1172/JCI70212
153. Wesolowski, R., Markowitz, J., and Carson, W. E. III (2013). Myeloid derived suppressor cells-a new therapeutic target in the treatment of cancer. J. Immunother. Cancer 1, 10. doi: 10.1186/2051-1426-1-10
154. Wherry, E. J., and Kurachi, M. (2015). Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15, 486-499. doi: 10.1038/nri3862
155. Wichert, M., and Krall, N. (2015). Targeting carbonic anhydrase IX with small organic ligands. Curr. Opin. Chem. Biol. 26, 48-54. doi: 10.1016/j.cbpa.2015.02.005
156. Wilson, W. R., and Hay, M. P. (2011). Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11, 393-410. doi: 10.1038/nrc3064
157. Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., et al. (2013). Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133. doi: 10.1056/NEJMoa1302369
158. Wong, C. C., Gilkes, D. M., Zhang, H., Chen, J., Wei, H., Chaturvedi, P., et al. (2011). Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc. Natl. Acad. Sci. U.S.A. 108, 16369-16374. doi: 10.1073/pnas.1113483108
159. Xu, C., Lo, A., Yammanuru, A., Tallarico, A. S., Brady, K., Murakami, A., et al. (2010). Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology. PLoS ONE 5:e9625. doi: 10.1371/journal.pone.0009625
160. Yang, J., AlTahan, A., Jones, D. T., Buffa, F. M., Bridges, E., Interiano, R. B., et al. (2015). Estrogen receptor-alpha directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer. Proc. Natl. Acad. Sci. U.S.A. 112, 15172-15177. doi: 10.1073/pnas.1422015112
161. Zatovicova, M., Jelenska, L., Hulikova, A., Csaderova, L., Ditte, Z., Ditte, P., et al. (2010). Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr. Pharm. Des. 16, 3255-3263. doi: 10.2174/138161210793429832
162. Zatovicova, M., Jelenska, L., Hulikova, A., Ditte, P., Ditte, Z., Csaderova, L., et al. (2014). Monoclonal antibody G250 targeting CA: binding specificity, internalization and therapeutic effects in a non-renal cancer model. Int. J. Oncol. 45, 2455-2467. doi: 10.3892/ijo.2014.2658
163. Zou, W. (2006). Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6, 295-307. doi: 10.1038/nri1806